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Background: Pulmonary arterial hypertension (PAH) has been associated with hemolytic condi-
tions such as sickle cell disease but the possible role of hemolysis in the pathogenesis or path-
ophysiology of other forms of PAH has not been studied. Erythrocyte lifespan is the gold-
standard test of hemolysis and may be measured by assaying erythrocyte creatine (EC) levels.
EC decreases as the erythrocyte ages, so patients with hemolysis have high EC levels.
Methods: We measured EC and other parameters of hemolysis in patients with idiopathic and
connective tissue associated PAH and normal controls.
Results: In patients with PAH (nZ 40), EC levels were higher than in controls nZ 30 (patients
EC 1.72 mcmol/g HgB 95%CI[1.51, 1.96], controls EC 1.05 mcmol/g HgB [0.93, 1.19],
p < 0.0001). High levels of EC correlated with worse 6 min walk (r Z 0.42, p < 0.0001)
and worse functional class (pZ 0.002). Other indirect indices of hemolysis (total lactate dehy-
drogenase, red cell distribution width) were also increased in patients with PAH relative to
controls.
Conclusions: There is evidence of subclinical hemolysis in patients with PAH, and higher levels
of hemolysis are associated with poorer exercise capacity.
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Hemolysis in PAH patients 595Introduction ParticipantsPulmonary arterial hypertension (PAH) is a catastrophic
disease affecting mostly young people.1 The term PAH refers
to a specific hemodynamic phenotype of pulmonary hyper-
tension (PH, defined as mean pulmonary artery pressure
>25 mmHg) with low left-sided cardiac pressures and high
pulmonary vascular resistance. The diagnosis given to an
individual patient is one of the subdivisions of the PAH class e
idiopathic PAH, hereditary PAH, PAH associated with medical
conditions suchas connective tissuediseases, congenital heart
disease etc.1 The pathogenesis of PAH is complex and incom-
pletely understood although inflammation and dysfunction
of growth factor regulation are central to the process.1
Over the last decade there has been increasing interest in
hemolysis as a potential cause of pulmonary hypertension.
Free hemoglobin,when released from the erythrocyte acts as
a ‘sump’ for nitric oxide (NO), and promotes endothelial
dysfunction with thrombosis, inflammation, vasoconstriction
and smooth muscle proliferation in the capillaries e the
hyperhemolysis paradigm.2 Similar pathophysiological
changes are also seen in PAH.3 In a study of hemoglo-
binediaspirin solution given to patients after cardiac surgery
as a blood-product alternative, a dose dependent rise in
pulmonary artery pressure was observed.4 Pulmonary hyper-
tension has been reported in almost all chronic hemolytic
diseases, suchas the thalassemiasand sickle cell anemia.5,6 In
themost recent PH consensus document, hemolysis has been
accepted as an ‘associated condition’ PAH subclass, although
many patients with hemolysis have PH associated with left
heart disease or anemia-induced high cardiac output.1,7
There are case reports of PAH-associated micro-angiopathic
hemolysis.8,9 A recent work also described an increase in red
cell distribution width (RDW) in PAH patients, a parameter
which may increase in hemolytic anemia.10
There are many laboratory parameters of hemolysis. The
gold-standard test is tomeasure red-blood-cell (RBC) lifespan
or half-life, which is reduced in hemolytic diseases.11 Hemo-
globin, hematocrit, reticulocyte counts and biochemical
parameters (LDH, bilirubin, haptoglobin) are also useful,
although theseparametersmaybeaffectedbynon-hemolytic
factors such as bonemarrow function, inflammation and liver
disease.11 RBC lifespan is measured by radio-labeling RBCs,
re-injecting the cells into the patient and observing elimina-
tion of the radio-isotope over time.12 These techniques are
not commonly available outside of research laboratories. An
alternative is to assay Erythrocyte Creatine (EC) levels, since
RBC creatine levels decrease as the cell ages.13 EC levels
correlate well with the gold-standard 51-Cr labeling tech-
nique.14 The clinical utility of EC has been established in
a cohort of patients with hemolytic anemia and hemolysis
caused by mechanical heart valves.13,15
We hypothesized that hemolysis might be present in PAH
and this study hypothesis was that EC levels will be higher
in PAH patients than in controls.
Methods
The study was approved by the Institutional Research Board
of Rabin Medical Center and all subjects gave written
informed consent to participate.We enrolled patients during routine follow-up in the PH
clinic at our center. Inclusion criteria for the PAH group
were based on the standard hemodynamic criteria (Mean
PAP >25 mmHg, PCWP 15 mmHg and PVR >3 Wood Units).
Patients with idiopathic, hereditary or connective tissue
disease associated PAH were eligible. Healthy control
subjects were invited to participate, typically drawn from
hospital staff or family members accompanying patients to
the clinic. Exclusion criteria were known hemolytic
disease, glucose-6-phosphatase deficiency, blood trans-
fusion within 3 months or clinically evident blood loss
within 3 months of study enrollment. Physiological and
demographic data were extracted from the medical
record.Sample analysis
After giving informed consent, venous blood samples were
drawn from each patient. Complete blood count and full
chemistry panel were performed routinely in the hospital
laboratory (Chemistry - Olympus AU2700, Olympus, Melville
NY; Hematology-Advia 120, Siemens, Deerfield, IL). The EC
was performed as per the technique described in detail
elsewhere.13 In brief, plasma and buffy coat are aspirated
from the blood sample after centrifugation. A small sample
of mixed packed RBCs is then hemolyzed in a four-fold
volume of 1 g/L saponin solution over 20 min at room
temperature. Aliquots of hemolyzed RBCs were then frozen
at 80 C until analysis. Hemosylate was deproteinized
with 0.15 mol/L Ba(OH)2 and 0.15 mol/L ZnSO4. Superna-
tant was obtained by centrifugation and filtration. Creatine
concentration in the supernatant was measured with the
enzymatic assay method involving creatine amidinohy-
drolase, sarcosine oxidase and peroxidase.13 Measured data
were expressed as micromole creatine per gram of hemo-
globin (mcmol/g Hb). Aliquots of serum were collected
from centrifuged clotted-blood and stored at 80 C for
LDH isoenzyme assay (Hydragel 150 assay, Sebia, Norcross,
GA).Statistical analysis
Subjects were grouped for analysis according to their
enrollment diagnosis. Data were tabulated as Mean [95%
Confidence Intervals] (CI). Parameters found to be signifi-
cantly right-skewed were log transformed before analysis,
with mean/CI reported as anti-logs.16 Differences between
groups were tested with Student’s t-test, analysis of vari-
ance (ANOVA), the Wilcoxon Ranked Sums test or the Chi-
Squared test as appropriate. The relationship between
parameters of interest was modeled by linear modeling or
general linear modeling, as required by the type of data
analyzed. We performed a series of pre-planned post-hoc
analyses to evaluate the relationship between EC and
traditional hemolytic parameters, PAH sub-diagnoses, use
of PAH-specific medication disease severity. All
analyses were performed on R statistical software
version 2.11.1.17
Table 1 Participants in the study e demographic and laboratory results.
PAH Normals p value
Age 52 [47, 56] 41 [31, 45] 0.01
Sex (M/F) 11/29 14/16 0.10*
PAH Subdiagnosis Idiopathic 24
Connective Tissue 16
PAH treatment Pre-treatment 23
PDE5-I 7
ERA 11
Prostanoid 10
Monotherapy 8
Combination 9
Hemoglobin (g/dl) 13.3 [12.7, 14.0] 14.0 [13.5, 14.4] 0.15
RDW (%) 15.2 [14.6, 15.9] 12.8 [12.6, 13.0] <0.0001y
Erythrocyte creatine (mcmol/g Hb) 1.72 [1.51, 1.96] 1.05 [0.93, 1.19] <0.0001
LDH total (units/l) 494 [454, 539] 348 [323, 374] <0.0001
LDH-1% 25.2 [23.5, 27.0] 27.3 [25.6, 29.2] 0.10
AST (units/l) 24 [21, 28] 21 [19, 23] 0.12
ALT (units/l) 22 [18, 26] 18 [15, 22] 0.15
Total Bilirubin (mg/dl) 0.65 [0.55, 0.75] 0.56 [0.47, 0.66] 0.22
Unconjugated Bilirubin (mg/dl) 0.46 [0.37, 0.57] 0.45 [0.38, 0.54] 0.89
Haptoglobin (mg/dl) 111 [93, 134] 97 [84, 112] 0.24
NT-proBNP (pg/ml) 461 [291, 732] Not measured e
All data are presented as mean [95% confidence interval] except for count data. All p values represent the result of a t-test except where
marked: *Chi-Squared, yWilcoxon Rank Sum test.
Abbreviations: AST, Aspartate Aminotransferase; ALT, Alanine aminotransferase; LDH, Lactate Dehydrogenase; RDW, Red cell distri-
bution width; BNP, Brain natriuretic peptide; PAH, Pulmonary Arterial Hypertension; PDE5-I, Phosphodiesterase inhibitor; ERA, Endo-
thelin Receptor Anatagonist.
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Seventy subjects were enrolled (Table 1). Patients with PAH
were older than controls (pZ 0.01). Patients with PAH had
significantly higher levels of erythrocyte creatine and LDH,
Fig. 1. RDW was also significantly higher in PAH compared to
controls.Figure 1 Erythrocyte Creatine levels in the different diag-
nostic groups. PAH patients are grouped together for analysis.Post-hoc analysis of erythrocyte creatine
We correlated EC with other accepted measurements of
hemolysis with linear regression. EC correlated significantly
with RDW (r Z 0.57, p < 0.0001), LDH (r Z 0.49,
p < 0.0001) and Hb (r Z 0.40, p < 0.0001), but not with
haptoglobin, AST and bilirubin. In a subgroup analysis, EC
was highest in PAH-connective tissue disease (2.06 95%CI
[1.68, 2.53]), followed by idiopathic PAH (1.54 95%CI[1.32,
1.86]) and then normals (1.05 95%CI[0.93, 1.19]); ANOVA
p < 0.0001, Tukey test p  0.05 for all comparisons. EC
levels were not different between groups of patients taking
or not taking PAH-specific medications, when analyzed as
treated vs untreated (t-test, pZ 0.44) or when grouped by
class of PAH medication (ANOVA, p Z 0.54).
In the PAH subject group, we analyzed the interaction
between EC and disease severity. We found a significant
negative correlation between Erythrocyte Creatine and
6 min walk distance (rZ 0.42, p < 0.0001), Fig. 2. There
were also significantly higher EC levels in patients withworse
NYHA functional class: NYHA I-II (1.38 95%CI[1.19, 1.61]) orNYHA III-IV (2.04 95%CI[1.71, 2.44]) pZ 0.002, Fig. 3. There
was no significant correlation between EC and NT-proBNP
(r Z 0.18, p Z 0.27). No significant correlations were
found between echocardiographically estimated SPAP or the
presence of right ventricular dysfunction. Over 36 months of
follow-up, 13/40 PAH subjects died. There was no significant
difference in EC between the survivors (1.75 95%CI[1.51,
2.03]) and non-survivors (1.71 95%CI[1.29, 2.26]) pZ 0.97.
Figure 2 Correlation between Erythrocyte Creatine levels
and 6 min walk. PAH patients were analyzed together as
a group.
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We analyzed hemolytic parameters in 40 patients with PAH
and 30 healthy controls. We demonstrated that RBC lifespan
(as assessedby ErythrocyteCreatineEC) is shorter in patients
with PAH, with highest values seen in patients with PAH
associated with connective tissue disease. This indicates
that subclinical hemolysis is present in patients with PAH.
As far as we know, this is the first investigation of hemo-
lysis in PAH patients. We measured an index of RBC survival
rather than derived/indirect measures of hemolysis such as
LDH. This gives a strong support to our hypothesis, since RBC
survival is the gold-standard test of hemolysis.11 Levels of ECFigure 3 Erythrocyte Creatine levels in the PAH patients
according to disease severity. Patients were assigned to two
groups - mild disease (NYHA I-II) or severe disease (NYHA III-IV).in PAH patients, especially those with connective tissue
disease were only slightly lower than patients with recog-
nizedhemolysis frommechanical heart valves (2.16mcmol/g
Hb, 95%CI[1.89, 2.43]).15 Patients with overt hemolytic
anemia have the highest reported EC levels (5.77 mcmol/g
Hb, 95%CI[4.33, 8.16]).13 Although we did not measure the
gold-standard test of RBC lifespan (51-Cr labeling), EC is an
established index of hemolysis which correlates with the
gold-standard.13,14 Another interesting phenomenonwas the
correlation between shortened RBC survival (high EC) and
worse exercise capacity. This is interesting because poor
exercise capacity is a known risk factor for mortality,
although in this small sample there was no difference in EC
between survivors and non-survivors. The PAH cohort
included untreated and treated patients, since some
(n Z 23) were recruited during their diagnostic workup
before commencement of therapy. We did not establish any
effect of therapy on EC although this finding must be inter-
preted with caution due to the small sample size. The
prognostic significance of EC and the effect of medication on
EC can only be established in a larger study.
It is not possible to determine from the current study
whether the hemolysis present in PAH patients represents
a cause, effect or epi-phenomenon of the illness. Highest
levels of EC were observed in PAH patients with connective
tissue disease (scleroderma or lupus in this cohort). Both
scleroderma and lupus are associated with hemolysis via
micro-angiopathic or auto-immune mechanisms, respec-
tively. Hemolysis in PAH has only been reported in isolated
case reports, where patients also had thrombocytopenia.9,8
We speculate that these patients may have had occult
lupus presenting as PAH, since thrombocytopenia is unusual
in the presentation of idiopathic PAH. The theory that
hemolysis promotes PH by depleting nitric oxide (NO) is
derived from study of patients with sickle cell disease,
where large amounts of RBC contents are spilled into the
plasma during a crisis.2 Some authors have questioned
whether the hyperhemolysis paradigm is sufficient to
explain the degree of PH in sickle patients.11 Given that
hemolysis during a sickle crisis is clinically significant
compared to the subclinical hemolysis we observed in the
PAH patients, it seems unlikely that a hyperhemolysis
paradigm is a primary cause of PAH. However, as Hebbel
points out, there are many other potentially toxic
substances released from a hemolyzed RBC such as argi-
nase and RBC microparticles, and these may also
contribute to the development of PH. Intuitively it is more
likely that hemolysis-associated loss of NO might exacer-
bate vasoconstriction in the already sick endothelial bed of
the diseased PAH lung.11 This might explain the correlation
between high EC levels and lower 6 min and worse NYHA
functional class, and also the finding that PAH patients with
high RDW have worse mortality.10 Further studies are
clearly needed to better define the nature of the associa-
tion between hemolysis and PAH.Conclusion
To summarize, there is biochemical evidence of subclinical
hemolysis in patients with PAH, although the cause and
consequences of this process are not yet clear. Increased
598 B.D. Fox et al.hemolysis is associated with worse exercise capacity. We
consider this work to be hypothesis-generating.Authors’ contributions
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